On November 5, 2026, a clinical trial update was recorded for a study titled "The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer." The trial, registered as NCT04927416, is a Phase 2 study. Its current status is listed as recruiting.
DOTATATE is a somatostatin analog used in this trial as part of a PET/CT imaging approach for patients with metastatic thyroid cancer. Somatostatin itself remains classified as unapproved and is used in research contexts such as this one.
The trial update does not include any reported results or outcome data at this time. No efficacy or safety conclusions have been stated for this study based on the information available. The listed status reflects only that the trial continues to enroll participants as of the update date.
Readers interested in the broader background of somatostatin and its research applications can consult the compound overview for additional context.